Leila Parand is an assistant clinical professor of neurology at the University of California, Los Angeles
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al
Monitoring and Follow-Up Care Regular medical supervision is essential when using GLP-1 medications, regardless of where you purchase them
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
The resulting solution should be clear
PMID: 37366315 | doi:10.1056/NEJMoa2301972 Rosenstock J et al